An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
Trial details
- Registry ID
- NCT07449702
- Drugs studied
- ORKA-001
TrialRedline tracks 6 clinical trials sponsored by Oruka Therapeutics, Inc.: 6 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| An Open-Label Extension Study of ORKA-001 in Participants With Plaque PsoriasisNCT07449702 | ORKA-001 | Recruiting | 2030-05Estimated |
| ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis SuppurativaNCT07783542 | ORKA-002 | Recruiting | 2028-10Estimated |
| An Open-label Study With Maintenance Dosing of ORKA-002 in Participants With Moderate-to-Severe Plaque PsoriasisNCT07933783 | ORKA-002 | Enrolling by invitation | 2029-07-01Estimated |
| Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque PsoriasisNCT07474792 | ORKA-002 | Active not recruiting | 2027-10Estimated |
| Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque PsoriasisNCT07290569 | ORKA-001 | Active not recruiting | 2026-10-21Actual |
| ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque PsoriasisNCT07090330 | ORKA-001 Induction Dose, ORKA-001 Maintenance Dose | Active not recruiting | 2026-03-25Actual |
Names as written in the registry records.
NCT07290569 · Oruka Therapeutics, Inc.
Before: Estimated. After: Actual.
Before: Jun 2027. After: 21 Oct 2026.
NCT07474792 · Oruka Therapeutics, Inc.
Before: Recruiting. After: Active not recruiting.
NCT07290569 · Oruka Therapeutics, Inc.
Before: Recruiting. After: Active not recruiting.
NCT07090330 · Oruka Therapeutics, Inc.
Before: Estimated. After: Actual.
Before: Apr 2026. After: 25 Mar 2026.
NCT07449702 · Oruka Therapeutics, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Incidence of Treatment-emergent Adverse Events (TEAEs) and TEAEs of Special Interest (TEAESIs). After: Measure: Incidence of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs of Special Interest (TEAESIs).
Before: 80 participants (planned). After: 240 participants (planned).
Before: Nov 2028. After: May 2030.
NCT07474792 · Oruka Therapeutics, Inc.
Before: Not yet recruiting. After: Recruiting.
NCT07090330 · Oruka Therapeutics, Inc.
Before: Sep 2026. After: Apr 2026.
Before: Recruiting. After: Active not recruiting.